Compare CYTK & DRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | DRS |
|---|---|---|
| Founded | 1997 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.8B |
| IPO Year | 2004 | N/A |
| Metric | CYTK | DRS |
|---|---|---|
| Price | $63.78 | $40.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 6 |
| Target Price | ★ $84.81 | $46.83 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | ★ 0.88% |
| EPS Growth | N/A | ★ 33.93 |
| EPS | N/A | ★ 0.99 |
| Revenue | $87,211,000.00 | ★ $3,569,000,000.00 |
| Revenue This Year | $339.72 | $11.94 |
| Revenue Next Year | $79.08 | $6.66 |
| P/E Ratio | ★ N/A | $41.43 |
| Revenue Growth | ★ 2609.26 | 12.27 |
| 52 Week Low | $29.31 | $28.17 |
| 52 Week High | $70.98 | $49.31 |
| Indicator | CYTK | DRS |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 65.30 |
| Support Level | $62.25 | $40.10 |
| Resistance Level | $65.38 | $41.99 |
| Average True Range (ATR) | 2.93 | 1.40 |
| MACD | 0.06 | 0.18 |
| Stochastic Oscillator | 64.02 | 70.42 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Leonardo DRS Inc is a provider of defense products and technologies that are used across land, air, sea, space, and cyber domains. The company is in the design, development, and manufacture of Advanced sensing, network computing, force protection, and electric power and propulsion technologies and solutions. The company has two segments: Advanced Sensing and Computing, which generates the majority of revenue, and the Integrated Mission Systems segment. The Advanced Sensing and Computing segment is engaged in designing, developing, and manufacturing sensing and network computing technology that enables real-time situational awareness required for enhanced operational decision-making and execution by the customers.